Heydari Maryam, Rezayi Majid, Ruscica Massimiliano, Jpamialahamdi Tannaz, Johnston Thomas P, Sahebkar Amirhossein
Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Arch Med Sci Atheroscler Dis. 2023 Dec 30;8:e128-e139. doi: 10.5114/amsad/176653. eCollection 2023.
Pathophysiological, epidemiological and genetic studies convincingly showed lipoprotein(a) (Lp(a)) to be a causal mediator of atherosclerotic cardiovascular disease (ASCVD). This happens through a myriad of mechanisms including activation of innate immune cells, endothelial cells as well as platelets. Although these certainties whether or not Lp(a) is ready for prime-time clinical use remain debated. Thus, remit of the present review is to provide an overview of different methods that have been employed for the measurement of Lp(a). The methods include dynamic light scattering, multi-angle light scattering analysis, near-field imaging, sedimentation, gel filtration, and electron microscopy. The development of multiple Lp(a) detection methods is vital for improved prediction of ASCVD risk.
病理生理学、流行病学和遗传学研究令人信服地表明,脂蛋白(a) [Lp(a)] 是动脉粥样硬化性心血管疾病 (ASCVD) 的因果介质。这是通过多种机制发生的,包括激活先天免疫细胞、内皮细胞以及血小板。尽管Lp(a) 是否已准备好用于临床的定论仍存在争议。因此,本综述的目的是概述已用于测量Lp(a) 的不同方法。这些方法包括动态光散射、多角度光散射分析、近场成像、沉降、凝胶过滤和电子显微镜。多种Lp(a) 检测方法的发展对于改善ASCVD 风险预测至关重要。